Clinical Research Progress | Expert Consultation Meeting for Trantinterol Hydrochloride Tablets Successfully Held

Recently, an expert consultation meeting for trantinterol hydrochloride tablets, organized by Beijing Leadingpharm, was held in Beijing. The meeting brought together experts from clinical medicine, drug registration, pharmaceutical R&D, and biostatistics, with the aim of systematically reviewing the project’s R&D data and defining the subsequent clinical registration pathway.
 

Attendees included:

Sponsor representatives: Professor Cheng Maosheng, former President of Shenyang Pharmaceutical University; and Mr. Yan Dong, General Manager of Shenyang Dashan Pharmaceutical Co., Ltd.Lead site: Professor Cao Zhaolong, Chief Physician and Principal Investigator (PI) at Peking University People’s Hospital.Professor Ding Xinmin, Chief Physician at Beijing Shijitan Hospital, Capital Medical University.Dr. Song Zhu, Associate Chief Physician at Peking University Third Hospital.Professor Yin Ping, Department of Biostatistics, Tongji Medical College, Huazhong University of Science and Technology.CRO representatives: Mr. Zhang Ronghuo, Executive President of Leadingpharm and General Manager of Zhengzhou Deep Blue Ocean Biopharmaceutical Technology Co., Ltd.; Mr. Kang Jianlei, Executive President and Chief Technology Officer of Leadingpharm; and Ms. Yuan Shaoxiong, Vice General Manager and Medical Commercial Director of Beijing Leadingpharm · Deep Blue Ocean (Zhengzhou).The meeting was moderated by Mr. Zhu Haobin, Vice General Manager of Beijing Leadingpharm · Deep Blue Ocean (Zhengzhou).

Sponsor representative: Professor Cheng Maosheng, former President of Shenyang Pharmaceutical University

Lead site PI: Professor Cao Zhaolong, Peking University People’s Hospital
 

Against the backdrop of evolving regulatory requirements, the meeting conducted a comprehensive review of all available non‑clinical and clinical study data for trantinterol hydrochloride tablets. Based on the latest drug registration technical standards, the experts discussed the product’s clinical value positioning, formulation‑related clinical benefit differences, and clinical data outcomes.
 

Combining current clinical practice in the respiratory field with drug evaluation trends, the expert panel provided optimization recommendations for subsequent trial design, statistical considerations, data quality, and implementation details, and reached a professional consensus on clinical advancement strategies.
 

This consultation meeting laid a solid foundation for the continued development of trantinterol hydrochloride tablets. The project team will refine the clinical strategy based on expert opinions and, while ensuring scientific rigor and compliance, accelerate the product’s path to market, with the goal of enriching clinical treatment options in the relevant therapeutic area.

-END-